ArticleScientific reports2026
Integrated molecular and histological profiling of preeclampsia suggests angiogenic dysregulation associated with maternal and fetal outcomes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Preeclampsia (PE) is a potentially life-threatening multisystem disorder affecting maternal and fetal health and is associated with impaired angiogenesis, endothelial dysfunction, inflammation, and apoptosis. In this study, we characterized molecular, histopathological, and clinical alterations in placentas from 30 women with PE compared with 30 normotensive controls. Placental tissues underwent macroscopic evaluation, histopathology, immunohistochemistry for α-Klotho, endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and tumor necrosis factor-α (TNF-α), alongside TUNEL assay for apoptosis. PE pregnancies were associated with earlier delivery, lower neonatal birth weight, reduced placental weight and volume, and decreased maternal total protein and albumin levels. Histologically, PE placentas exhibited increased syncytial knots, intervillous fibrin deposition, distal villous hypoplasia, chorangiosis, avascular villi, and calcifications. Immunohistochemical analyses indicated reduced expression of α-Klotho, eNOS, VEGF, and PlGF, with increased TNF-α expression and higher apoptotic index. α-Klotho expression correlated positively with angiogenic markers, placental weight, and birth weight, and negatively with TNF-α and apoptosis. Multivariate regression analyses suggested that PE is associated with increased placental apoptosis and TNF-α expression, as well as reduced α-Klotho, eNOS, VEGF, and PlGF expression, and with lower birth weight, primarily mediated by prematurity. Early-onset PE exhibited more pronounced α-Klotho reduction with relatively preserved eNOS expression, suggesting potential compensatory endothelial responses, while magnesium sulfate or antihypertensive therapy did not significantly influence molecular profiles. These findings suggest that PE is linked to coordinated alterations in angiogenic, endothelial, and inflammatory pathways associated with placental structural changes and adverse perinatal outcomes. Observed alterations in α-Klotho and angiogenic markers highlight potential pathways for further investigation into targeted molecular interventions. This study is limited by its single-center, and relatively small sample size, which may limit generalizability, and causal relationships cannot be established; further multi-center prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.